Search Results - "Alligood, K J"

Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb®, GW572016) in an expanded panel of human normal and tumour cell lines by Rusnak, D. W., Alligood, K. J., Mullin, R. J., Spehar, G. M., Arenas-Elliott, C., Martin, A.-M., Degenhardt, Y., Rudolph, S. K., Jr Haws, T. F., Hudson-Curtis, B. L., Gilmer, T. M.

“…  Objective: Lapatinib (Tykerb®, GW572016), a potent inhibitor of the catalytic activities of epidermal growth factor receptor (EGFR) and human epidermal…”
Get full text

Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways by Xia, Wenle, Mullin, Robert J, Keith, Barry R, Liu, Lei-Hua, Ma, Hong, Rusnak, David W, Owens, Gary, Alligood, Krystal J, Spector, Neil L

“…Dual EGFR/erbB2 inhibition is an attractive therapeutic strategy for epithelial tumors, as ligand-induced erbB2/EGFR heterodimerization triggers potent…”
Get full text

The Effects of the Novel, Reversible Epidermal Growth Factor Receptor/ErbB-2 Tyrosine Kinase Inhibitor, GW2016, on the Growth of Human Normal and Tumor-derived Cell Lines in Vitro and in Vivo by Rusnak, D W, Lackey, K, Affleck, K, Wood, E R, Alligood, K J, Rhodes, N, Keith, B R, Murray, D M, Knight, W B, Mullin, R J, Gilmer, T M

“…The epidermal growth factor receptor (EGFR) and ErbB-2 transmembrane tyrosine kinases are currently being targeted by various mechanisms in the treatment of…”
Get full text

The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: Potential therapy for cancer by RUSNAK, David W, AFFLECK, Karen, JOWETT, Amanda, STABLES, Jeremy, TOPLEY, Peter, WOOD, Edgar R, BRIGNOLA, Perry S, KADWELL, Sue H, REEP, Bryan R, MULLIN, Robert J, ALLIGOOD, Krystal J, KEITH, Barry R, COCKERILL, Stuart G, CROSBY, Renae M, MURRAY, Doris M, KNIGHT, W. Blaine, GILMER, Tona M, LACKEY, Karen, STUBBERFIELD, Colin, HARRIS, Robert, PAGE, Martin, SMITH, Kathryn J, GUNTRIP, Stephen B, CARTER, Malcolm C, SHAW, Robert J

“…The type I receptor tyrosine kinases constitute a family of transmembrane proteins involved in various aspects of cell growth and survival and have been…”
Get full text

The formation of a covalent complex between a dipeptide ligand and the src SH2 domain by Alligood, Krystal J., Charifson, Paul S., Crosby, Renae, Consler, Thomas G., Feldman, Paul L., Gampe, Robert T., Gilmer, Tona M., Jordan, Steven R., Milstead, Mark W., Mohr, Christopher, Peel, Michael R., Rocque, Warren, Rodriguez, Marc, Rusnak, David W., Shewchuk, Lisa M., Sternbach, Daniel D.

“…The X-ray crystal structure of the src SH2 domain revealed the presence of a thiol residue (Cys 188) located proximal to the phosphotyrosine portion of a…”
Get full text

Potent Dipeptide Inhibitors of the pp60c-src SH2 Domain by PACOFSKY, Gregory J., LACKEY, Karen, ALLIGOOD, Krystal J., BERMAN, Judd, CHARIFSON, Paul S., CROSBY, Renae M., DORSEY, George F., FELDMAN, Paul L., GILMER, Tona M., HUMMEL, Conrad W., JORDAN, Steven R., MOHR, Christopher, SHEWCHUK, Lisa M., STERNBACH, Daniel D., RODRIGUEZ, Marc

“…The design, synthesis, and evaluation of dipeptide analogues as ligands for the pp60c-src SH2 domain are described. The critical binding interactions between…”
Get full text

A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): Relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells by WOOD, Edgar R, TRUESDALE, Anne T, ALLIGOOD, Krystal J, RUSNAK, David W, GILMER, Tona M, SHEWCHUK, Lisa, MCDONALD, Octerloney B, YUAN, Derek, HASSELL, Anne, DICKERSON, Scott H, ELLIS, Byron, PENNISI, Christopher, HORNE, Earnest, LACKEY, Karen

“…GW572016 (Lapatinib) is a tyrosine kinase inhibitor in clinical development for cancer that is a potent dual inhibitor of epidermal growth factor receptor…”
Get full text

Monoclonal antibodies generated against recombinant ATM support kinase activity by Alligood, K J, Milla, M, Rhodes, N, Ellis, B, Kilpatrick, K E, Lee, A, Gilmer, T M, Lansing, T J

“…We report on the rapid generation of two monoclonal antibodies, ATM A16.35 and ATM D16.11, that bind to the kinase domain of mutated ataxia telangiectasia…”
Get more information

Comparison of the biochemical and kinetic properties of the type 1 receptor tyrosine kinase intracellular domains. Demonstration of differential sensitivity to kinase inhibitors by Brignola, Perry S, Lackey, Karen, Kadwell, Sue H, Hoffman, Christine, Horne, Earnest, Carter, H Luke, Stuart, J Darren, Blackburn, Kevin, Moyer, Mary B, Alligood, Krystal J, Knight, Wilson B, Wood, Edgar R

“…Epidermal growth factor receptor (EGFR), ErbB-2, and ErbB-4 are members of the type 1 receptor tyrosine kinase family. Overexpression of these receptors,…”
Get full text

Alkynyl pyrimidines as dual EGFR/ErbB2 kinase inhibitors by Waterson, Alex G., Stevens, Kirk L., Reno, Michael J., Zhang, Yue-Mei, Boros, Eric E., Bouvier, Frederic, Rastagar, Abdullah, Uehling, David E., Dickerson, Scott H., Reep, Bryan, McDonald, Octerloney B., Wood, Edgar R., Rusnak, David W., Alligood, Krystal J., Rudolph, Sharon K.

“…Anilinoalkynylpyrimidines were prepared and evaluated as dual EGFR/ErbB2 kinase inhibitors. A preference was found for substituted phenyl and heteroaromatic…”
Get full text